SCHEMBL3008167

SCHEMBL3008167

CCc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccccc4C(F)(F)F)CC3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.58
LMNA P02545 4/20 0.58
MAPK1 P28482 4/20 0.58
MEN1 O00255 3/20 0.58
ALDH1A1 P00352 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
MAPT P10636 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.53
HTT P42858 2/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
HSD11B1 P28845 1/20 0.48
GBA1 P04062 2/20 0.47
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KCNQ1 P51787 1/20 0.43
CHRM4 P08173 1/20 0.43
DCTPP1 Q9H773 1/20 0.43
KDM1A O60341 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3116696 0.93 KMT2A (0.56) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3016409 0.89 KMT2A (0.61) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3007681 0.89 LMNA (0.63) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3023065 0.88 LMNA (0.55) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3014667 0.87 MAPT (0.61) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3011530 0.87 KMT2A (0.51) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3007753 0.87 MAPT (0.58) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3650646 0.86 LMNA (0.52) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3002208 0.86 LMNA (0.62) KMT2ALMNAMAPK1MEN1ALDH1A1
SCHEMBL3010909 0.85 LMNA (0.61) KMT2ALMNAMAPK1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885LMNA 80/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.